Journal
ARTHRITIS RESEARCH & THERAPY
Volume 13, Issue 2, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/ar3306
Keywords
-
Categories
Funding
- Forest Laboratories
- holds stocks in Merck and Company, Inc.
- Novartis
- Elan Corporation
- Pfizer
- Cypress Bioscience, and Forest
- NIH/NIAMS [AR057578]
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR057578] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Pain is a key component of most rheumatologic diseases. In fibromyalgia, the importance of central nervous system pain mechanisms (for example, loss of descending analgesic activity and central sensitization) is well documented. A few studies have also noted alterations in central pain processing in osteoarthritis, and some data, including the observation of widespread pain sensitivity, suggest that central pain-processing defects may alter the pain response in rheumatoid arthritis patients. When central pain is identified, different classes of analgesics (for example, serotonin-norepinephrine reuptake inhibitors, alpha(2)delta ligands) may be more effective than drugs that treat peripheral or nociceptive pain (for example, nonsteroidal anti-inflammatory drugs and opioids).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available